Document Classification

Section Type: RESULTS

Text: The incidence of all predefined end points was lower in the metoprolol CR/XL group than in the placebo group, including total mortality or all-cause hospitalizations (the prespecified second primary end point ; 641 vs 767 events ; risk reduction, 19 % ; 95 % confidence interval [CI], 10 % -27 % ; P <. 001) ; total mortality or hospitalizations due to worsening heart failure (311 vs 439 events ; risk reduction, 31 % ; 95 % CI, 20 % -40 % ; P <. 001), number of hospitalizations due to worsening heart failure (317 vs 451 ; P <. 001) ; and number of days in hospital due to worsening heart failure (3401 vs 5303 days ; P <. 001).